JAK2 gRNA (BRDN0001149125) Citations (1)

Originally described in: Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9.
Doench JG, Fusi N, Sullender M, Hegde M, Vaimberg EW, Donovan KF, Smith I, Tothova Z, Wilen C, Orchard R, Virgin HW, Listgarten J, Root DE Nat Biotechnol. 2016 Jan 18. doi: 10.1038/nbt.3437. PubMed Journal

---

Articles Citing JAK2 gRNA (BRDN0001149125)

Articles
Hypoxic conditions confer chemoresistance to crizotinib but not to imatinib in chronic myeloid leukemia cells. Avinery L, Regev D, Khamaisi H, Gopas J, Mahajna J. Hematol Transfus Cell Ther. 2026 Jan 10;48(2):106240. doi: 10.1016/j.htct.2025.106240. PubMed

If you have published an article using this material, please email us at to have your article added to this page.